AIM:RLM

Stock Analysis Report

Executive Summary

Realm Therapeutics plc does not have significant operations.

Snowflake

Fundamentals

Flawless balance sheet and overvalued.

Risks

  • Realm Therapeutics has significant price volatility in the past 3 months.
  • Realm Therapeutics's last earnings update was 226 days ago.
  • Realm Therapeutics is not covered by any analysts.

Share Price & News

How has Realm Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-5.7%

AIM:RLM

2.0%

GB Pharmaceuticals

1.1%

GB Market


1 Year Return

-71.0%

AIM:RLM

19.0%

GB Pharmaceuticals

-4.8%

GB Market

RLM underperformed the Pharmaceuticals industry which returned 16.7% over the past year.

RLM underperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -0% over the past year.


Share holder returns

RLMIndustryMarket
7 Day-5.7%2.0%1.1%
30 Day18.3%14.7%-3.5%
90 Day35.6%20.1%-0.7%
1 Year-71.0%-71.0%22.6%19.0%-0.3%-4.8%
3 Year-60.8%-60.8%51.7%37.1%19.4%5.3%
5 Year-76.5%-76.5%94.9%63.0%27.8%0.9%

Price Volatility Vs. Market

How volatile is Realm Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Realm Therapeutics undervalued based on future cash flows and its price relative to the stock market?

0.63x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Realm Therapeutics to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Realm Therapeutics to establish if it is available at substantial discount.


Price Based on Earnings

Realm Therapeutics is loss making, we can't compare its value to the GB Pharmaceuticals industry average.

Realm Therapeutics is loss making, we can't compare the value of its earnings to the United Kingdom of Great Britain and Northern Ireland market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Realm Therapeutics, we can't assess if its growth is good value.


Price Based on Value of Assets

Realm Therapeutics is good value based on assets compared to the GB Pharmaceuticals industry average.


Next Steps

Future Growth

How is Realm Therapeutics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

28.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Realm Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Realm Therapeutics performed over the past 5 years?

-16.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Realm Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Realm Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Realm Therapeutics's 1-year growth to the GB Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Realm Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Realm Therapeutics has efficiently used its assets last year compared to the GB Pharmaceuticals industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Realm Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Realm Therapeutics's financial position?


Financial Position Analysis

Realm Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Realm Therapeutics has no long term commitments.


Debt to Equity History and Analysis

Realm Therapeutics has no debt.

Realm Therapeutics has no debt compared to 5 years ago when it was 7.6%.


Balance Sheet

Low level of unsold assets.

Realm Therapeutics has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Realm Therapeutics has sufficient cash runway for 1.6 years based on current free cash flow.

Realm Therapeutics has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 41.3% each year.


Next Steps

Dividend

What is Realm Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Realm Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Realm Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Realm Therapeutics has not reported any payouts.

Unable to verify if Realm Therapeutics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Realm Therapeutics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Realm Therapeutics's salary, the management and board of directors tenure and is there insider trading?

3.8yrs

Average management tenure


CEO

Alex Martin (50yo)

3.8yrs

Tenure

US$861,600

Compensation

Mr. John Alexander Martin, also known as Alex, has been the Chief Executive Officer and Executive Director of PuriCore Plc since June 12, 2015. Mr. Martin has more than 25 years' experience having held sen ...


CEO Compensation Analysis

Alex's remuneration is higher than average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.

Alex's compensation has increased whilst company is loss making.


Management Age and Tenure

3.8yrs

Average Tenure

51yo

Average Age

The tenure for the Realm Therapeutics management team is about average.


Board Age and Tenure

3.8yrs

Average Tenure

53yo

Average Age

The tenure for the Realm Therapeutics board of directors is about average.


Insider Trading

No 3 month insider trading information.


Recent Insider Transactions

BuyUS$520,87321 Feb 19
BAVARIA Industries Group AG
EntityCompany
Shares6,944,948
Max PriceUS$0.075
SellUS$299,99930 Nov 18
RA Capital Management, LLC
EntityCompany
Shares3,750,000
Max PriceUS$0.08
SellUS$45,00029 Nov 18
RA Capital Management, LLC
EntityCompany
Shares500,000
Max PriceUS$0.09
SellUS$18,71009 Oct 18
RA Capital Management, LLC
EntityCompany
Shares210,000
Max PriceUS$0.096

Ownership Breakdown


Management Team

  • Alex Martin (50yo)

    CEO & Executive Director

    • Tenure: 3.8yrs
    • Compensation: US$861.60k
  • Marella Thorell (51yo)

    CFO, COO

    • Tenure: 6.0yrs
    • Compensation: US$595.38k
  • Christian Peters (56yo)

    Chief Medical Officer

    • Tenure: 2.9yrs

Board Members

  • Bill Birkett (70yo)

    Senior Independent Non-Executive Director

    • Tenure: 11.1yrs
    • Compensation: US$54.38k
  • Simba Gill (53yo)

    Non-Executive Director

    • Tenure: 3.0yrs
    • Compensation: US$90.38k
  • Sandy Zweifach (62yo)

    Non-Executive Director

    • Tenure: 1.3yrs
    • Compensation: US$31.82k
  • Alex Martin (50yo)

    CEO & Executive Director

    • Tenure: 3.8yrs
    • Compensation: US$861.60k
  • Ivan Gergel (57yo)

    Independent Non-Executive Director

    • Tenure: 2.2yrs
    • Compensation: US$73.08k
  • Charles Alexander Spicer (53yo)

    Non-Executive Chairman

    • Tenure: 4.8yrs
    • Compensation: US$84.01k
  • Marella Thorell (51yo)

    CFO, COO

    • Tenure: 6.0yrs
    • Compensation: US$595.38k

Company Information

Realm Therapeutics plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Realm Therapeutics plc
  • Ticker: RLM
  • Exchange: AIM
  • Founded: 2016
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£13.405m
  • Shares outstanding: 116.56m
  • Website: https://www.realmtx.com

Number of Employees


Location

  • Realm Therapeutics plc
  • 267 Great Valley Parkway
  • Malvern
  • Pennsylvania
  • 19355
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RLMAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPJun 2006
3HDBST (Boerse-Stuttgart)YesOrdinary SharesDEEURJun 2006
RLMNasdaqCM (Nasdaq Capital Market)SPONSORED ADSUSUSDJul 2018

Biography

Realm Therapeutics Plc, a biopharmaceutical company, focuses on developing therapies for the treatment of immune-mediated diseases in adults and children. Its product pipeline includes PRO22, a topical gel ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/03/28 21:41
End of Day Share Price2019/03/26 00:00
Earnings2018/06/30
Annual Earnings2017/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.